{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:37:50Z","timestamp":1789958270714,"version":"4.0.1"},"reference-count":29,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2017,10,4]],"date-time":"2017-10-04T00:00:00Z","timestamp":1507075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["PF\u201000299804"],"award-info":[{"award-number":["PF\u201000299804"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To harness the frontline therapy in advanced penile squamous cell carcinoma (PSCC), for which chemotherapy exerts moderate activity but poor efficacy. Dacomitinib is an irreversible, pan\u2010epidermal growth factor receptor (HER) inhibitor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>\n                      In a phase 2 study (NCT01728233), patients received dacomitinib 45\u00a0mg\/day, orally, continuously. Inclusion criteria were SCC histology, clinical stage N\n                      <jats:sub>2\u20133<\/jats:sub>\n                      or M\n                      <jats:sub>1<\/jats:sub>\n                      (Tumour\u2010Node\u2010Metastasis classification system 2009), and no prior chemotherapy administration. The primary endpoint was the objective response rate (ORR, according to the Response Evaluation Criteria in Solid Tumors, version 1.1). Stopping rules based on the Bayesian posterior probability (PP) to demonstrate that the ORR exceeded 20% were set.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>From June 2013 to October 2016, 28 patients were treated. Eight (28.6%) had visceral metastases, 14 (50%) had pelvic and 17 (60.7%) clinically involved bilateral lymph nodes. One complete and eight partial responses were obtained (ORR 32.1%, 80% credibility interval 21.0\u201343.0%). The median (interquartile range [IQR]) follow\u2010up duration was 19.8 (6.3\u201325.7) months; 12\u2010month progression\u2010free survival was 26.2% (95% confidence interval [CI] 13.2\u201351.9); 12\u2010month overall survival (OS) was 54.9% (95% CI 36.4\u201382.8). The median (IQR) OS of locally advanced patients was 20 (11.1\u2013not reached) months. The Bayesian PP of exceeding the 20% ORR target was 92.3%. Grade 3 adverse events (skin rash) were seen in three patients (10.7%). Tissue samples from 25 patients were analysed. Only two patients had high\u2010risk human papillomavirus\u2010positive tumours. Epidermal growth factor receptor (EGFR) amplification was found in four patients (equally responders and non\u2010responders) and it was confirmed in all post\u2010dacomitinib samples. Telomerase reverse transcriptase (TERT) mutations were found in responders only (60%), and phosphatidylinositol 3\u2010kinase\/mammalian target of rapamycin (PI3K\/mTOR) pathway gene mutations were found in 42.9% of responders vs 8.3% of non\u2010responders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Dacomitinib was active and well tolerated in patients with advanced PSCC and may represent an option when combined chemotherapy cannot be administered. Mutations in downstream effectors of EGFR signalling in relation to dacomitinib activity deserve further studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/bju.14013","type":"journal-article","created":{"date-parts":[[2017,9,18]],"date-time":"2017-09-18T10:12:53Z","timestamp":1505729573000},"page":"348-356","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":94,"title":["First\u2010line therapy with dacomitinib, an orally available pan\u2010HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open\u2010label, single\u2010arm, single\u2010centre, phase 2 study"],"prefix":"10.1111","volume":"121","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"first","affiliation":[{"name":"Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Lo Vullo","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Trials Organization Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Perrone","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Raggi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Calareso","sequence":"additional","affiliation":[{"name":"Department of Radiology Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Nicolai","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Piva","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Biasoni","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Catanzaro","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tullio","family":"Torelli","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Stagni","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Togliardi","sequence":"additional","affiliation":[{"name":"Pharmacy Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Busico","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annunziata","family":"Gloghini","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adele","family":"Testi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Mariani","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Trials Organization Unit Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvioni","sequence":"additional","affiliation":[{"name":"Urology Unit Department of Surgery Fondazione IRCCS Istituto Nazionale dei Tumori Milano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,10,4]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ucl.2016.06.009"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.10.017"},{"key":"e_1_2_7_4_1","unstructured":"National Comprehensive Cancer Network: NCCN guidelines: Penile cancer. Available at:https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/penile.pdf. Accessed 15 March 2017"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.5477"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.620"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2014.06.005"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.07.009"},{"key":"e_1_2_7_9_1","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2017.02.002","article-title":"Clinical outcomes of perioperative chemotherapy in patients with locally advanced penile squamous cell carcinoma: results of a multicentre analysis","author":"Necchi A","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.10.007"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.8367"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12450"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2015.08.001"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-1756"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds503"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70452-8"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70461-9"},{"key":"e_1_2_7_18_1","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1002\/cncr.28561","article-title":"A phase 2 trial of dacomitinib (PF\u201000299804), an oral, irreversible pan\u2010HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non\u2010small cell lung cancer after failure of prior chemotherapy and erlotinib","volume":"120","author":"Rackamp KL","year":"2014","journal-title":"Cancer"},{"key":"e_1_2_7_19_1","volume-title":"TNM Classification of Malignant Tumours","author":"Sobin LH","year":"2009"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(99)00229-4"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2013.10.140"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2016.03.005"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji112"},{"key":"e_1_2_7_25_1","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.humpath.2015.06.026","article-title":"Reproducibility between messenger RNA real\u2010time polymerase chain reaction and messenger RNA in\u00a0situ hybridization in oropharingeal squamous cell carcinoma patients","volume":"47","author":"Ciniselli CM","year":"2016","journal-title":"Hum Pathol"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn149"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw227"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1004"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0241"},{"key":"e_1_2_7_30_1","article-title":"Gene expression profiling of advanced penile squamous cell carcinoma receiving cisplatin\u2010based chemotherapy improves prognostication and identifies potential therapeutic targets","author":"Necchi A","year":"2016","journal-title":"Eur Urol Focus"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.14013","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.14013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T14:33:18Z","timestamp":1761748398000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.14013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["10.1111\/bju.14013"],"URL":"https:\/\/doi.org\/10.1111\/bju.14013","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,4]]},"assertion":[{"value":"2017-10-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}